C Quach1, O Baclic2. 1. NACI Pneumococcal Working Group Chair, Montréal, QC. 2. Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, ON.
Abstract
BACKGROUND: Since 2015, pneumococcal 13-valent conjugate vaccine (PNEU-C-13) has been authorized for the prevention of invasive pneumococcal disease (IPD) and pneumococcal community-acquired pneumonia (CAP) in adults. Adults with immunocompromising conditions are still recommended to receive PNEU-C-13 followed by the pneumococcal 23-valent polysaccharide vaccine (PNEU-P-23). NACI guidance has been requested on the use of PNEU-C-13 vaccine in immunocompetent adults 65 years of age and older. OBJECTIVES: To make recommendations, at the individual level, for the use of PNEU-C-13 in immunocompetent adults 65 years of age and over. METHODS: The NACI Pneumococcal Working Group (PWG) reviewed key questions and performed an evidence review and synthesis. In consideration of the burden of illness to be prevented, the target population, safety, immunogenicity, efficacy and effectiveness of the vaccine, the PWG proposed recommendations for vaccine use to NACI. All evidence was rated and reported in evidence tables. NACI approved specific evidence-based recommendations and elucidated the rationale and relevant considerations in the statement update. RESULTS: NACI identified and reviewed evidence from one randomized controlled trial investigating the efficacy of PNEU-C-13 to prevent IPD and CAP in adults who were immunocompetent at enrollment and three clinical trials assessing the immunogenicity in immunocompetent and immunocompromised adults. CONCLUSIONS: Based on reviewed evidence, NACI issued new recommendations for the use of pneumococcal vaccines in immunocompetent adults 65 years of age and older.
BACKGROUND: Since 2015, pneumococcal 13-valent conjugate vaccine (PNEU-C-13) has been authorized for the prevention of invasive pneumococcal disease (IPD) and pneumococcal community-acquired pneumonia (CAP) in adults. Adults with immunocompromising conditions are still recommended to receive PNEU-C-13 followed by the pneumococcal 23-valent polysaccharide vaccine (PNEU-P-23). NACI guidance has been requested on the use of PNEU-C-13 vaccine in immunocompetent adults 65 years of age and older. OBJECTIVES: To make recommendations, at the individual level, for the use of PNEU-C-13 in immunocompetent adults 65 years of age and over. METHODS: The NACI Pneumococcal Working Group (PWG) reviewed key questions and performed an evidence review and synthesis. In consideration of the burden of illness to be prevented, the target population, safety, immunogenicity, efficacy and effectiveness of the vaccine, the PWG proposed recommendations for vaccine use to NACI. All evidence was rated and reported in evidence tables. NACI approved specific evidence-based recommendations and elucidated the rationale and relevant considerations in the statement update. RESULTS: NACI identified and reviewed evidence from one randomized controlled trial investigating the efficacy of PNEU-C-13 to prevent IPD and CAP in adults who were immunocompetent at enrollment and three clinical trials assessing the immunogenicity in immunocompetent and immunocompromised adults. CONCLUSIONS: Based on reviewed evidence, NACI issued new recommendations for the use of pneumococcal vaccines in immunocompetent adults 65 years of age and older.
Authors: Marshall J Glesby; Wendy Watson; Cynthia Brinson; Richard N Greenberg; Jacob P Lalezari; Daniel Skiest; Vani Sundaraiyer; Robert Natuk; Alejandra Gurtman; Daniel A Scott; Emilio A Emini; William C Gruber; Beate Schmoele-Thoma Journal: J Infect Dis Date: 2014-11-13 Impact factor: 5.226
Authors: Marc J M Bonten; Susanne M Huijts; Marieke Bolkenbaas; Chris Webber; Scott Patterson; Samantha Gault; Cornelis H van Werkhoven; Anna M M van Deursen; Elisabeth A M Sanders; Theo J M Verheij; Michael Patton; Anne McDonough; Anita Moradoghli-Haftvani; Helen Smith; Tracey Mellelieu; Michael W Pride; Graham Crowther; Beate Schmoele-Thoma; Daniel A Scott; Kathrin U Jansen; Rita Lobatto; Bas Oosterman; Nils Visser; Esther Caspers; Andre Smorenburg; Emilio A Emini; William C Gruber; Diederick E Grobbee Journal: N Engl J Med Date: 2015-03-19 Impact factor: 91.245
Authors: Juan Carlos Tinoco; Christine Juergens; Guillermo M Ruiz Palacios; Jorge Vazquez-Narvaez; Hermann Leo Enkerlin-Pauwells; Vani Sundaraiyer; Sudam Pathirana; Elena Kalinina; William C Gruber; Daniel A Scott; Beate Schmoele-Thoma Journal: Clin Vaccine Immunol Date: 2014-12-10
Authors: Lisa A Jackson; Alejandra Gurtman; Martin van Cleeff; Kathrin U Jansen; Deepthi Jayawardene; Carmel Devlin; Daniel A Scott; Emilio A Emini; William C Gruber; Beate Schmoele-Thoma Journal: Vaccine Date: 2013-05-18 Impact factor: 3.641